We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


New iQue® Screener PLUS Delivers Rapid, High-Content Cellular Analysis

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "New iQue® Screener PLUS Delivers Rapid, High-Content Cellular Analysis"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

The iQue Screener platform is an integrated instrument, software, and reagent system that enhances the screening workflow, from sample preparation to results. It enables rapid, high-content, multiplexed analysis of cells and beads in suspension in 96-, 384- and 1536-well plates. The system’s patented sample delivery system enables rapid plate processing (less than five minutes for 96 wells), and assays can be miniaturized to conserve precious sample and reduce reagent use. Software-assisted automation, analysis and experiment-level visualization tools reveal deep insight into complex biology through an easy-to-use, intuitive interface.

IntelliCyt iQue Screener Image.jpg

The iQue Screener PLUS expands choice and flexibility, adding a 405nm violet laser to the blue (488nm) and red (640nm) lasers, along with 15 detection channels. 13 fluorescence and two scatter detectors provide richer content through higher order multiplexing. The expanded range of dyes and fluorochromes for the violet laser adds flexibility and enhanced performance, with lower spectral overlap, increased brightness, better signal-to-noise ratio and broader applicability.

“Our iQue Screener platform has been successfully applied across a range of drug discovery applications. It has been adopted by every top pharmaceutical company, 

many leading biotech companies and prestigious academic institutes,” said R. Terry Dunlay, CEO and founder of IntelliCyt Corporation. “We believe the launch of the new iQue Screener PLUS will accelerate immunology and immunotherapy discovery research and enable scientists to develop novel and effective treatments for cancer and other serious diseases.”